

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 4

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/815,557
Filing Date March 31, 2004
First Named Inventor Engelhardt, John
Group Art Unit 1633
Examiner Name Hill, Kevin

Attorney Docket No: 875.085US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date if Appropriate
	US-20030003583A1	01/02/2003	Hirsch, R, et al.	06/10/2002
	US-6,475,537	11/05/2002	King, W, et al.	07/27/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ¹
	WO-0075365A3	12/14/2000	Engelhardt, John F., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Advisory Action mailed 11-03-2004, 3 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Amendment filed 08-03-2005, 13 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Amendment filed 11-18-2004, 11 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Final Office Action mailed 02-24-2003, 11 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Final Office Action mailed 06-18-2004, 8 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Non Final Office Action mailed 01-07-2005, 10 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Non Final Office Action mailed 06-26-2002, 13 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Non Final Office Action mailed 08-12-2003, 8 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Notice of Allowance mailed 09-12-2005, 10 pgs	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 909. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) : Applicant is to place a check mark here if English language translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

Application Number	10/815,557
Filing Date	March 31, 2004
First Named Inventor	Engelhardt, John
Group Art Unit	1633
Examiner Name	Hill, Kevin

Sheet 2 of 4

Attorney Docket No: 875.085US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Preliminary Amendment filed 10-12-2000, 2 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Response filed 01-12-2004 to Non Final Office Action mailed 08-12-2003, 12 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Response filed 05-18-2005 to Non Final Office Action mailed 01-07-2005, 14 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Response filed 05-30-2003 to Final Office Action mailed 02-24-2003, 13 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Response filed 10-18-2004 to Final Office Action mailed 06-18-2004, 13 pgs	
		Application Serial No. 09/689,136 (Atty. Ref. 875.032US1) Response filed 11-26-2002 to Non Final Office Action mailed 06-26-2002, 14 pgs	
		Application Serial No. 10/815,262 (Atty Ref 875.074US1) Non-Final Office Action mailed 10-30-07, 24 pgs	
		Application Serial No. 10/815,262 (Atty Ref 875.074US1), Amendment and Response mailed 1/31/08 re Non-final Office Action mailed 10/30/07, 26 pages	
		Application Serial No. 10/815,262 (Atty. Ref. 875.074US1) Amendment filed 08-22-2007, 1 pg	
		Application Serial No. 10/815,262 (Atty. Ref. 875.074US1) Non Final Office Action mailed 05-15-2007, 25 pgs	
		Application Serial No. 10/815,262 (Atty. Ref. 875.074US1) Response filed 08-14-2007 to Non Final Office Action mailed 05-15-2007, 24 pgs	
		Application Serial No. 10/815,262 (Atty. Ref. 875.074US1), Final Office Action mailed 04-23-2008., 24 pgs	
		Application Serial No. 11/301,601 (875.032US2), Non-Final Office Action mailed 07/12/2007, 29 pgs.	
		Application Serial No. 11/301,601 (Atty Ref 875.032US2), Response filed 10/11/07 to Non-Final Office Action mailed 7/12/07, 14 pages	
		Application Serial No. 11/301,601 (Atty. Ref. 875.032US3) Preliminary Amendment filed 08-07-2007, 9 pgs	
		Application Serial No. 11/301,601, (Atty Ref 875.032US2) Non-Final Office Action mailed 7/12/2007, 29 pgs	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/815,557
Filing Date	March 31, 2004
First Named Inventor	Engelhardt, John
Group Art Unit	1633
Examiner Name	Hill, Kevin

Sheet 3 of 4

Attorney Docket No: 875.085US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Application Serial No. 11/301,601, (Atty Ref 875.032US2) Preliminary Amendment filed 12/13/2005, 9 pgs	
		Application Serial No. 11/301,601, (Atty Ref 875.032US2) Response filed 8/11/2007 Non-Final Office Action mailed 7/12/2007, 14 pgs	
		Application Serial No. 11/301601 (Atty Ref. 875.032US2) Final Office Action mailed 12/13/2007, 15 pgs	
		Application Serial No. 11/890,777, (Atty Ref 875.032US3) Preliminary Amendment filed 8/7/2007, 9 pgs	
		"Enzyme database entry for EC number 3.4.22". „ [online]. Retrieved from the Internet: < http://ca.expasy.org/enzyme/3.4.22 >, (June 19, 2007), 2 pgs.	
		"Written Opinion for corresponding PCT Application No. PCT/US2004/009950", (Attorney Docket No. 875.085WO1), (03/08/2005), 15 pgs.	
		"Written Opinion for corresponding PCT Application No. PCT/US2004/010045", (Attorney Docket No. 875.074WO1), (January 10, 2005), 15 pgs	
		CARTER, B. J., "Adeno-Associated Virus Vectors in Clinical Trials", <u>2005 Hum. Gene Ther.</u> 16, 541-550	
		DJALDETTI, M., et al., "SEM observations on the effect of anthracycline drugs on cultured newborn rat cardiomyocytes", <u>Basic Res Cardiol.</u> , 83(6):672-7 (1988).	
		ECK, et al., <u>Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 5, McGraw-Hill, NY.</u>	
		GONCALVES, M. A., "Adeno-associated virus: from defective virus to effective vector", <u>Viral J.</u> , 2, (May 6, 2005), 17 pgs.	
		GROSS, R. et al., "Clinical problems of optimum bioavailability, in particular in cytostatic therapy" (ABSTRACT ONLY), <u>Arzneimittelforschung</u> , 26(1A): 130-5 (1976)	
		KAPTURCZAK, M. H., et al., "Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery: Improvements in vector Design and Viral Production Enhance Potential to prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type I Diabetes", <u>Current Molecular Medicine</u> , (2001), 245-258	
		MAH, C., et al., "Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy", <u>Molecular Therapy</u> , 6(1), (2001), 106-112	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/815,557
Filing Date	March 31, 2004
First Named Inventor	Engelhardt, John
Group Art Unit	1633
Examiner Name	Hill, Kevin

Sheet 4 of 4

Attorney Docket No: 875.085US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARSHALL, E., "Gene Therapy's Growing Plans", <u>Science</u> 269(5227), (1995), 1050-1055	
		ORKIN, S. H., et al., "Report and recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy", [on-line]. [retrieved 2007-7-6]. Retrieved from the Internet: <URL: file:///E:/Enablement Rejections/Generally usefu art/wwwnihgov-news-panelrephm.htm>, (December 7, 1995), 39 pgs.	
		ROSS, G., et al., "Gene Therapy in the United States: A Five-Year Status Report", <u>Human Gene Therapy</u> , 7, (1996), 1781-1790	
		RUBANYI, G. M., "The Future of Human Gene Therapy", <u>2001 Mol Aspects Med</u> , 22, 113-142	
		TENENBAUM, et al., "Cellular contaminants of adeno-associated virus vector stocks can enhance transduction", <u>Gene Therapy</u> , 6, (1999), 1045-1053	
		VERMA, I. M., et al., "Gene Therapy - Promises, Problems and Prospects", <u>Nature</u> , 389, (1997), 239-242	
		VOINEA, et al., "Designing of Intelligent liposomes for efficient delivery of drugs", <u>J. cell. Mol. Med.</u> , 6(4), (2002), 465-474	
		YALKINOGLU, A. O., et al., "Inhibition of N-methyl-N'-nitro-N-nitrosoguanidine-induced methotrexate and adriamycin resistance in CHO cells by adeno-associated virus type 2", <u>Cancer</u> , 45(6), (1990), 1195-1203	
		ZHANG, F., et al., "Proteasome Function is Regulated by Cyclic AMP-dependent Protein Kinase through Phosphorylation of Rpt6", <u>The Journal of Biological Chemistry</u> , 282(31), (8/3/07), 22460-22471	

EXAMINER

/Kevin Hill/

DATE CONSIDERED

07/24/2008

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/